Melanotan I

A selective MC1R agonist, structurally related to Melanotan II but far more receptor-selective. Its pharmaceutical form, afamelanotide, is FDA-approved (as Scenesse) for a rare light-sensitivity disorder — a meaningfully different regulatory story than Melanotan II.

A note on naming and regulatory status

"Melanotan I" (MT-I) and afamelanotide are essentially the same molecule — afamelanotide is the pharmaceutical/branded name for what research-chemical vendors sell as Melanotan I. Unlike its more famous, non-selective relative Melanotan II, Melanotan I/afamelanotide is FDA-approved (since 2019, brand name Scenesse) for a specific rare disease indication: erythropoietic protoporphyria (EPP), a genetic condition causing severe, painful light sensitivity.

Overview

Melanotan I is a selective agonist of the MC1R (melanocortin 1 receptor) — the receptor most directly responsible for skin pigmentation. Its improved selectivity relative to Melanotan II (which non-selectively hits MC1R, MC3R, MC4R, and MC5R) is the key structural distinction between the two compounds, and the likely reason it had a cleaner path to approval for a legitimate medical indication.

Proposed Mechanism of Action

By selectively activating MC1R on melanocytes, Melanotan I stimulates melanin production, increasing skin pigmentation and providing some protective buffer against UV/visible light-triggered phototoxic reactions — the specific mechanism relevant to its approved EPP indication, where patients experience severe pain and skin damage from ordinary light exposure due to a porphyrin metabolism disorder.

Research Context

The cited Phase 3 trial tested the approved subcutaneous implant formulation in patients with erythropoietic protoporphyria, measuring time spent in direct sunlight without pain as the primary outcome. Afamelanotide-treated patients tolerated meaningfully more light exposure than placebo, with a generally favorable safety profile, supporting its subsequent approval in the EU (2014), the US (2019), and Australia (2020).

Limitations of the Current Evidence

The approval and pivotal trial are specific to erythropoietic protoporphyria — a narrow, rare-disease context. The approved delivery method (a controlled-release implant placed by a clinician) is also specific and different from injectable formulations sold as "Melanotan I" by research-chemical vendors, which have not been studied or approved in that form.
As with Melanotan II, off-label tanning use is a different context from the approved medical indication, with a different (and less studied) risk-benefit profile.